📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
21 announcements match the current filters (relevance ≥ 5).
Divi's Labs Q3 FY26 Consolidated Revenue up 12% YoY to ₹2,604 Cr; PAT Flat at ₹583 Cr
Divi's Laboratories reported a 12.3% YoY growth in consolidated revenue at ₹2,604 crore for Q3 FY26. However, consolidated net profit remained nearly flat at ₹583 crore, compared to ₹589 crore in the previous year, primarily due to a one-time exceptional charge of ₹74 crore related to new Labour Codes. On a sequential basis, revenue and PAT declined by 4.1% and 15.4% respectively. Despite the flat PAT, the 9-month consolidated profit shows a healthy 18.8% growth YoY reaching ₹1,817 crore.
Key Highlights
Consolidated Revenue from operations grew 12.3% YoY to ₹2,604 crore.
Consolidated Net Profit stood at ₹583 crore, down 1% YoY, impacted by a ₹74 crore exceptional item.
Profit Before Tax (before exceptional items) increased 17.6% YoY to ₹854 crore.
Nine-month (9M FY26) consolidated PAT grew 18.8% YoY to ₹1,817 crore.
Forex gain for the quarter was significantly lower at ₹18 crore compared to ₹64 crore in the previous quarter.
👀 What to Watch
Investors should look past the one-time exceptional labour code impact and focus on the steady 12% top-line growth. While sequential performance was soft, the 9-month growth trajectory remains positive for long-term holders.
